Forget the diagnosis count. The researcher who helped the WHO reframe aging says function, not disease, is the better yardstick.

A new preprint links the company’s cell therapy to less brain inflammation in Alzheimer’s, just as it heads out on an ...

All three Phase 3 trials of the weekly shot ribupatide have finished enrolling, and the head-to-head against semaglutide is ...

Patent cliffs and falling R&D productivity push the biggest players toward other people's science – our report puts numbers ...

QIMA Life Sciences launches SQINGEVITY, bringing biological testing and clinical studies together to examine claims about ...

Monte Rosa’s NEK7-targeting drug pulled several heart-risk biomarkers toward healthy levels in 108 people with obesity.

Mighty Therapeutics and the University of Washington will use pilot data on elamipretide to design a larger trial in older ...

A Lancet Neurology study of 130 blood proteins in patients receiving lecanemab suggests amyloid clearance and cognitive ...

Ascensia partnership puts the London healthtech’s microsensor on the road to a European launch – with ambitions that run well ...

Aged beagle data hint at lower biological age and preliminary muscle changes with SIRT6c treatment, although key readouts ...

MUST’s RETRO-EPIGERNA team won $1 million and a place in the $81 million finals, though key trial details remain undisclosed.

Arvinas presented early biomarker data on ARV-102, an oral drug built to clear the LRRK2 protein, at a major Parkinson’s ...